Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis

Molecular Cancer Research

Volumn 1, Issue 1, 2002, Pages 2-11

  Cheng, Nikki ^a   Brantley, Dana M ^a   Liu, Hua ^a,b   Lin, Qin ^a   Enriquez, Miriam ^a   Gale, Nick ^c   Yancopoulos, George ^c   Cerretti, Douglas Pat ^b   Daniel, Thomas O ^a,b   Chen, Jin ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANTISENSE OLIGONUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; CHIMERIC PROTEIN; EPHRIN; EPHRIN RECEPTOR; FC RECEPTOR; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR EPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CORNEAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EPHRIN-A1; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; RECEPTOR, EPHA2; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0345269144     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Gale, N. W. and Yancopoulos, G. D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev., 13: 1055-1066, 1999.
2. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., and Holash, J. Vascular-specific growth factors and blood vessel formation. Nature, 407: 242-248, 2000.
3. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 376: 62-66, 1995.
4. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 376: 66-70, 1995.
5. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380: 435-439, 1996.
6. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 380: 439-442, 1996.
7. Haigh, J. J., Gerber, H. P., Ferrara, N., and Wagner, E. F. Conditional inactivation of VEGF-A in areas of collagen2al expression results in embryonic lethality in the heterozygous state. Development, 127: 1445-1453, 2000.
8. Miquerol, L., Langille, B. L., and Nagy, A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development, 127: 3941-3946, 2000.
9. Lin, P., Sankar, S., Shan, S., Dewhirst, M. W., Polverini, P. J., Quinn, T. Q., and Peters, K. G. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth & Differ., 9: 49-58, 1998.
10. Brekken, R. A., Overholser, J. P., Stastny, V. A., Waltenberger, J., Minna, J. D., and Thorpe, P. E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res., 60: 5117-5124, 2000.
11. Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Muller, M., Wood, J., Martiny-Baron, G., Unger, C., and Marme, D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res., 60: 4819-4824, 2000.
12. Vitaliti, A., Wittmer, M., Steiner, R., Wyder, L., Neri, D., and Klemenz, R. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res., 60: 4311-4314, 2000.
13. Wood, J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., Persohn, E., Rosel, J., Schnell, C., Stover, D., Theuer, A., Towbin, H., Wenger, F., Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K. H., Schneider, M. R., Drevs, J., Martiny-Baron, G., and Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 60: 2178-2189, 2000.
14. Vajkoczy, P., Menger, M. D., Vollmar, B., Schilling, L., Schmiedek, P., Hirth, K. P., Ullrich, A., and Fong, T. A. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia, 1: 31-41, 1999.
15. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly, T. J., Davis, S., Sato, T. N., and Yancopoulos, G. D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277: 55-60, 1997.
16. Asahara, T., Chen, D., Takahashi, T., Fujikawa, K., Kearney, M., Magner, M., Yancopoulos, G. D., and Isner, J. M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res., 83: 233-240, 1998.
17. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., and Wiegand, S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 284: 1994-1998, 1999.
18. Holder, N. and Klein, R. Eph receptors and ephrins: effectors of morphogenesis. Development, 126: 2033-2044, 1999.
19. Cheng, N., Brantley, D., and Chen, J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev., 13: 75-85, 2002.
20. Wang, H. U., Chen, Z. F., and Anderson, D. J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Epph-B4. Cell, 93: 741-753, 1998.
21. Adams, R. H., Wilkinson, G. A., Weiss, C., Diella, F., Gale, N. W., Deutsch, U., Risau, W., and Klein, R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev., 3: 295-306, 1999.
22. Gerety, S. S., Wang, H. U., Chen, Z. F., and Anderson, D. J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol. Cell, 4: 403-414, 1999.
23. Holzman, L. B., Marks, R. M., and Dixit, V. M. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol. Cell. Biol., 10: 5830-5838, 1990.
24. McBride, J. L. and Ruiz, J. C. ephrinA1 is expressed at sites of vascular development in the mouse. Mech. Dev., 77: 201-204, 1998.
25. Pandey, A., Shao, H., Marks, R. M., Polverini, P. J., and Dixit, V. M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science, 268: 567-569, 1995.
26. Daniel, T. O., Stein, E., Cerretti, D. P., St. John, P. L., Robert, B., and Abrahamson, D. R. ELK and LERK-2 in developing kidney and microvascular endothelial assembly. Kidney Int. Suppl., 57: S73-S81, 1996.
27. Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., and Pasquale, E. B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene, 19: 6043-6052, 2000.
28. Brantley, D. M., Cheng, N., Thompson, E. J., Lin, Q., Brekken, R. A., Thorpe, P. E., Muraoka, R. S., Cerretti, D. P., Pozzi, A., Jackson, D., Lin, C., and Chen, J. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene, 21: 7011-7026, 2002.
29. Chen, J., Nachebeh, A., Scherer, C., Ganju, P., Reith, A., Bronson, R., and Ruley, H. E. Germline inactivation of the murine Eck receptor tyrosine kinase by retroviral insertion. Oncogene, 12: 979-988, 1996.
30. Kenyon, B. M., Voest, E. E., Chen, C. C., Flynn, E., Folkman, J., and D'Amato, R. J. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci., 37: 1625-1632, 1996.
31. Phillips, G. D., Stone, A. M., Jones, B. D., Schultz, J. C., Whitehead, R. A., and Knighton, D. R. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo, 8: 961-965, 1994.
32. Griffioen, A. W. and Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev., 52: 237-268, 2000.
33. Kolizek, T. I., Weiss, C., Yancopoulos, G. D., Deutsch, U., and Risau, W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol., 8: 529-532, 1998.
34. Hess, A. R., Seftor, E. A., Gardner, L. M., Carles-Kinch, K., Schneider, G. B., Seftor, R. E., Kinch, M. S., and Hendrix, M. J. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res., 61: 3250-3255, 2001.
35. Gerber, H. P., McMurtrey, A., Kowalski, J., Keyt, B. A., Dixit, V., and Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phophatidylinositol 3′-kinases/Akt signal transduction pathway. J. Biol. Chem., 273: 30336-30434, 1998.
36. Rousseau, S., Houle, F., Landry, J., and Huot, J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene, 15: 2169-2177, 1997.
37. Holland, S. J., Gale, N. W., Mbamalu, G., Yancopoulos, G. D., Henkemeyer, M., and Pawson, T. Bidirectional signaling through the EPH-family receptor Nuk and its transmembrane ligands. Nature, 383: 722-725, 1996.
38. Bruckner, K., Pasquale, E. B., and Klein, R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science, 275: 1640-1643, 1997.
39. Davy, A., Nicholas, W. G., Murray, E. W., Klinghoffer, R. A., Soriano, P., Feuerstein, C., and Robbins, S. M. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev., 13: 3125-3135, 1999.
40. Huai, J. and Drescher, U. An ephrinA dependent signaling pathway controls integrin function and is linked to the tyrosine phosphorylation of a 120 kDa protein. J. Biol. Chem., 276: 6689-6694, 2001.
41. Daniel, T. O., Liu, H., Morrow, J. D., Crews, B. C., and Mamett, L. J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res., 59: 4574-4577, 1999.
42. Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., and Lawley, T. J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol., 99: 683-690, 1992.